Observational studyBMC cardiovascular disorders2025
Predicting one-year outcomes after TAVI: evidence from a two-site Swiss registry.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index for 1-Year Mortality After Transcatheter Aortic Valve Implantation.Journal of cardiovascular development and disease · 2026Article
- Transcatheter aortic valve implantation: latest evidence, gaps in knowledge, and future directions.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of patients undergoing transcatheter aortic valve implantation (TAVI) is rising. While TAVI improves survival, symptoms, and quality of life, ESC guidelines highlight the lack of validated tools to predict futile outcomes. Around 20% of intermediate- and high-risk patients die within one-year post-TAVI, underscoring the need for robust risk stratification.
objectivesTo develop and validate a multivariable model predicting one-year mortality after TAVI, using real-world data from two Swiss centers.
methodsWe analysed 2,053 patients who underwent TAVI between 2014 and 2022 at two centers in the Swiss TAVI Registry. The primary endpoint was all-cause mortality at one-year. Candidate variables were selected based on a 2024 scoping review, clinical expertise, and data availability. Variables associated with mortality (p < 0.2) in univariate Cox regression were included in a multivariate Cox model. Model performance was evaluated using ROC curves and Youden's index.
resultsAt 30 days, independent predictors of mortality were reduced left ventricular ejection fraction, COPD, peripheral artery disease, and age. At one-year, mortality was associated with atrial fibrillation, lower LVEF, mitral regurgitation grade, age, corticosteroid use, coronary artery disease, insulin-dependent diabetes, and reduced glomerular filtration rate. The model achieved an AUC of 0.814 for 30-day mortality and 0.763 at one-year, outperforming the STS score for short-term prediction (AUC 0.785).
conclusionThis study demonstrates the feasibility of building a one-year mortality prediction model after TAVI using standard clinical variables. With 2,053 patients from two centers, the model is a promising step toward Swiss-specific risk tools. Incorporating frailty or functional status may further improve performance. This model may support heart teams in shared decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.